In patients with lupus, belimumab blocks autoantibody production and B cell activation while maintaining overall immune competence, demonstrating that selective modulation of BAFF can provide therapeutic benefit while retaining key immune functions (134, 136). Here, TNFSF13B is linked to systemic lupus erythematosus.